During the next decade many genetic tests will become commercially available. A slow rate of diffusion of these tests prolongs inequity, as more people will not have access to them. If, however, diffusion outpaces the understanding of physicians offering the tests, or if they disregard concerns about autonomy and confidentiality, the chance of harm is increased. In this project, we will study factors influencing physicians' adoption of new genetic tests and their attitudes towards how tests should be provided. We will also study policies for developing and providing genetic tests and begin to explore consumer attitudes. By mailed questionnaire, we will compare physicians who have already offered a carrier test for cystic fibrosis to physicians who adopt the test while this study is in progress and to others who have not yet used it. We will examine the influence of physicians' knowledge of genetics and genetic tests, their perception of their patients' expectations regarding test use, their experience with and concerns about legal liability, and their sensitivity to whether their patients' insurance can pay for the test (or, if not, whether their patients can afford it) on whether they have actually used this test. By interviews and questionnaires, we will learn how major health care insurers decide when to include new innovative technologies, such as genetic tests, in their benefits packages and what factors influence their decisions. By a survey of biotechnology companies and clinical laboratories, we will explore policies and practices of organizations that are developing and/or providing genetic tests and the extent of genetic testing. The information will assist policy makers in deciding whether current statutes and regulations are adequate to assure safe and effective testing. By conducting focus groups of consumes with and without a family history of breast cancer, we will elicit patient attitudes toward autonomy under genetic test situations similar to those presented in the scenarios. We will also learn consumers' reactions to the ways physicians communicate information on genetic tests. Attitudes of African-American women toward genetic tests for breast cancer will be explicitly considered. The study will, therefore, identify the extent of departures from ethical norms in the diffusion of new genetic tests. It will suggest particular situations in which remedial educational interventions or policy changes could improve the safe and effective delivery of genetic tests.

Agency
National Institute of Health (NIH)
Institute
National Human Genome Research Institute (NHGRI)
Type
Research Project (R01)
Project #
5R01HG000026-06
Application #
2208368
Study Section
Genome Study Section (GNM)
Project Start
1990-05-01
Project End
1998-04-30
Budget Start
1995-05-01
Budget End
1996-04-30
Support Year
6
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Pediatrics
Type
Schools of Medicine
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Doksum, Teresa; Bernhardt, Barbara A; Holtzman, Neil A (2003) Does knowledge about the genetics of breast cancer differ between nongeneticist physicians who do or do not discuss or order BRCA testing? Genet Med 5:99-105
Doksum, T; Bernhardt, B A; Holtzman, N A (2001) Carrier screening for cystic fibrosis among Maryland obstetricians before and after the 1997 NIH Consensus Conference. Genet Test 5:111-6
Schoonmaker, M M; Bernhardt, B A; Holtzman, N A (2000) Factors influencing health insurers' decisions to cover new genetic technologies. Int J Technol Assess Health Care 16:178-89
Holtzman, N A (1998) Eugenics and genetic testing. Sci Context 11:397-417
Geller, G; Strauss, M; Bernhardt, B A et al. (1997) ""Decoding"" informed consent. Insights from women regarding breast cancer susceptibility testing. Hastings Cent Rep 27:28-33
Holtzman, N A (1996) Medical and ethical issues in genetic screening--an academic view. Environ Health Perspect 104 Suppl 5:987-90
Holtzman, N A (1994) Benefits and risks of emerging genetic technologies: the need for regulation. Clin Chem 40:1652-7
Holtzman, N A (1993) Primary care physicians as providers of frontline genetic services. Fetal Diagn Ther 8 Suppl 1:213-9
Geller, G; Tambor, E S; Chase, G A et al. (1993) Measuring physicians' tolerance for ambiguity and its relationship to their reported practices regarding genetic testing. Med Care 31:989-1001
Geller, G; Tambor, E S; Bernhardt, B A et al. (1993) Physicians' attitudes toward disclosure of genetic information to third parties. J Law Med Ethics 21:238-40

Showing the most recent 10 out of 14 publications